<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2017-600-609</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASES</subject></subj-group></article-categories><title-group><article-title>Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям</article-title><trans-title-group xml:lang="en"><trans-title>UPDATED EULAR GUIDELINES FOR THE MANAGEMENT OF GOUT. COMMENTS ON CERTAIN ITEMS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><email xlink:type="simple">elicmax@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии&#13;
им. В.А. Насоновой», Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>04</day><month>01</month><year>2018</year></pub-date><volume>55</volume><issue>6</issue><fpage>600</fpage><lpage>609</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2462">https://rsp.mediar-press.net/rsp/article/view/2462</self-uri><abstract><sec><title>В 2016 г</title><p>В 2016 г., по истечении 10 лет после публикации, впервые были обновлены международные рекомендации Европейской антиревматической лиги (EULAR) по лечению подагры. Заключительный вариант обновленных рекомендаций, включающий три базовых постулата и 11 позиций, оговаривающих принципы проведения симптоматической терапии острого приступа артрита и, что более важно, стратегии урат-снижающей терапии, направлен на возможность их практического использования; однако некоторые, не лишенные неоднозначных суждений, положения требуют обсуждения и пояснения, в том числе исходя из российских реалий.</p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="en"><p>In 2016, after 10 years since publication, the international guidelines of the European Antirheumatic League (EULAR) for the management of gout were updated for the first time. The final version of the updated guidelines includes three overarching postulates and 11 key recommendations evaluating principles of the symptomatic therapy of an acute attack of arthritis and, more importantly, strategies of urate-lowering therapy. The aim of the above-mentioned guidelines is the possibility of their practical use. However, some statements, which contain controversial judgments, require further discussion and clarification, also in the context of russian realities.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>подагра</kwd><kwd>мочевая кислота</kwd><kwd>урат-снижающая терапия</kwd><kwd>аллопуринол</kwd><kwd>фебуксостат</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gout</kwd><kwd>uric acid</kwd><kwd>urate-lowering therapy</kwd><kwd>allopurinol</kwd><kwd>febuxostat</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707</mixed-citation><mixed-citation xml:lang="en">Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004;63:1172-6. doi: 10.1136/ard.2004.023697</mixed-citation><mixed-citation xml:lang="en">Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004;63:1172-6. doi: 10.1136/ard.2004.023697</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350</mixed-citation><mixed-citation xml:lang="en">Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. doi: 10.1136/ard.2006.055269</mixed-citation><mixed-citation xml:lang="en">Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. doi: 10.1136/ard.2006.055269</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490-5.</mixed-citation><mixed-citation xml:lang="en">Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490-5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1136/annrheumdis-2011-200801</mixed-citation><mixed-citation xml:lang="en">doi: 10.1136/annrheumdis-2011-200801</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78:456-9. doi: 10.1016/j.jbspin.2011.05.010</mixed-citation><mixed-citation xml:lang="en">Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78:456-9. doi: 10.1016/j.jbspin.2011.05.010</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826-30.</mixed-citation><mixed-citation xml:lang="en">Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826-30.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1136/annrheumdis-2012-201676</mixed-citation><mixed-citation xml:lang="en">doi: 10.1136/annrheumdis-2012-201676</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015;67(4):588-92. doi: 10.1002/acr.22469</mixed-citation><mixed-citation xml:lang="en">Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015;67(4):588-92. doi: 10.1002/acr.22469</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431-46. doi: 10.1002/acr.21772</mixed-citation><mixed-citation xml:lang="en">Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431-46. doi: 10.1002/acr.21772</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349-5. doi: 10.1097/RHU.0b013e3182314d40</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011;17:349-5. doi: 10.1097/RHU.0b013e3182314d40</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71 (6):929-34. doi: 10.1136/annrheumdis-2011-200156</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71 (6):929-34. doi: 10.1136/annrheumdis-2011-200156</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Барскова ВГ, Денисов ИС. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. 2015;87(5):10-5 [Eliseev MS, Barskova VG, Denisov IS. Dynamics of clinical manifestations of gout in men (data from a 7-year retrospective observation). Terapevticheskii Arkhiv. 2015;87(5):10-5 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Барскова ВГ, Денисов ИС. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. 2015;87(5):10-5 [Eliseev MS, Barskova VG, Denisov IS. Dynamics of clinical manifestations of gout in men (data from a 7-year retrospective observation). Terapevticheskii Arkhiv. 2015;87(5):10-5 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Барскова ВГ. Диета при подагре. Доктор.Ру. 2011;(1):55-8 [Eliseev MS, Barskova VG. Diet for gout. Doktor.Ru. 2011;(1):55-8 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Барскова ВГ. Диета при подагре. Доктор.Ру. 2011;(1):55-8 [Eliseev MS, Barskova VG. Diet for gout. Doktor.Ru. 2011;(1):55-8 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ. Влияние продуктов растительного происхождения на уровень мочевой кислоты: обзор литературы. Терапия. 2017;(4):52-8 [Eliseev MS, Zhelyabina OV. The influence of vegetable products on the level of uric acid: a review of literature. Terapiya. 2017;(4):52-8 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Желябина ОВ. Влияние продуктов растительного происхождения на уровень мочевой кислоты: обзор литературы. Терапия. 2017;(4):52-8 [Eliseev MS, Zhelyabina OV. The influence of vegetable products on the level of uric acid: a review of literature. Terapiya. 2017;(4):52-8 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J. 2015;45(2):189-94. doi: 10.1111/imj.12661</mixed-citation><mixed-citation xml:lang="en">Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J. 2015;45(2):189-94. doi: 10.1111/imj.12661</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jalal DI, Chonchol M, Chen W, et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61:134-46.</mixed-citation><mixed-citation xml:lang="en">Jalal DI, Chonchol M, Chen W, et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61:134-46.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1053/j.ajkd.2012.07.021</mixed-citation><mixed-citation xml:lang="en">doi: 10.1053/j.ajkd.2012.07.021</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyper-uricemia in the US general population: NHANES 2007-2008. Am J Med. 2011;125:679-87.e1. doi: 10.1016/j.amjmed.2011.09.033</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyper-uricemia in the US general population: NHANES 2007-2008. Am J Med. 2011;125:679-87.e1. doi: 10.1016/j.amjmed.2011.09.033</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Кудаева ФМ, Гордеев АВ, Барскова ВГ. Скорость клубочковой фильтрации у больных подагрой и факторы, на нее влияющие. Современная ревматология. 2007;1(1):42-6 [Kudaeva FM, Gordeev AV, Barskova VG. Glomerular filtration rate in patients with gout and factors influencing the rate. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2007;1(1):42-46. (In Russ.)]. doi: 10.14412/1996-7012-2007-438</mixed-citation><mixed-citation xml:lang="en">Кудаева ФМ, Гордеев АВ, Барскова ВГ. Скорость клубочковой фильтрации у больных подагрой и факторы, на нее влияющие. Современная ревматология. 2007;1(1):42-6 [Kudaeva FM, Gordeev AV, Barskova VG. Glomerular filtration rate in patients with gout and factors influencing the rate. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2007;1(1):42-46. (In Russ.)]. doi: 10.14412/1996-7012-2007-438</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-96.</mixed-citation><mixed-citation xml:lang="en">Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-96.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1002/art.22014</mixed-citation><mixed-citation xml:lang="en">doi: 10.1002/art.22014</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900. doi: 10.1161/CIRCULATIONAHA.107.703389</mixed-citation><mixed-citation xml:lang="en">Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900. doi: 10.1161/CIRCULATIONAHA.107.703389</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69:1162-4. doi: 10.1136/ard.2009.122770</mixed-citation><mixed-citation xml:lang="en">De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69:1162-4. doi: 10.1136/ard.2009.122770</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2:e000282. doi: 10.1136/bmjopen-2011-000282</mixed-citation><mixed-citation xml:lang="en">Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012;2:e000282. doi: 10.1136/bmjopen-2011-000282</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177-82. doi: 10.1136/annrheumdis-2012-202421</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177-82. doi: 10.1136/annrheumdis-2012-202421</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2015;10:e0134088. doi: 10.1371/journal.pone.0134088</mixed-citation><mixed-citation xml:lang="en">Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2015;10:e0134088. doi: 10.1371/journal.pone.0134088</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252</mixed-citation><mixed-citation xml:lang="en">Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74:642-7. doi: 10.1136/annrheumdis-2014-205252</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Денисов ИС, Маркелова ЕИ и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевтический архив. 2017;89(5):10-9 [Eliseev MS, Denisov IS, Markelova EI, et al. Independent risk factors for the development of severe cardiovascular complications in men with gout: the results of a 7-year prospective study. Terapevticheskii Arkhiv. 2017;89(5):10-9 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Денисов ИС, Маркелова ЕИ и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевтический архив. 2017;89(5):10-9 [Eliseev MS, Denisov IS, Markelova EI, et al. Independent risk factors for the development of severe cardiovascular complications in men with gout: the results of a 7-year prospective study. Terapevticheskii Arkhiv. 2017;89(5):10-9 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Haj Mouhamed D, Ezzaher A, Neffati F, et al. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prevent Med. 2011;16(5):307-12. doi: 10.1007/s12199-010-0198-2</mixed-citation><mixed-citation xml:lang="en">Haj Mouhamed D, Ezzaher A, Neffati F, et al. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prevent Med. 2011;16(5):307-12. doi: 10.1007/s12199-010-0198-2</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hanna BE, Hamed JM, Touhala LM. Serum uric acid in smokers. Oman Med J. 2008;23(4):269-74.</mixed-citation><mixed-citation xml:lang="en">Hanna BE, Hamed JM, Touhala LM. Serum uric acid in smokers. Oman Med J. 2008;23(4):269-74.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Gee Teng G, Pan A, Yuan JM, Koh WP. Cigarette smoking and risk of incident gout in the Singapore Chinese Health Study. Arthritis Care Res (Hoboken). 2016;68(8):1135-42. doi: 10.1002/acr.22821</mixed-citation><mixed-citation xml:lang="en">Gee Teng G, Pan A, Yuan JM, Koh WP. Cigarette smoking and risk of incident gout in the Singapore Chinese Health Study. Arthritis Care Res (Hoboken). 2016;68(8):1135-42. doi: 10.1002/acr.22821</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford). 2015;54(1):91-5. doi: 10.1093/rheumatology/keu304</mixed-citation><mixed-citation xml:lang="en">Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford). 2015;54(1):91-5. doi: 10.1093/rheumatology/keu304</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-9. doi: 10.1016/j.semarthrit.2008.08.006</mixed-citation><mixed-citation xml:lang="en">Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-9. doi: 10.1016/j.semarthrit.2008.08.006</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Saseen JJ. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012;51(11):2004-12. doi: 10.1093/rheumatology/kes183</mixed-citation><mixed-citation xml:lang="en">Saseen JJ. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012;51(11):2004-12. doi: 10.1093/rheumatology/kes183</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014 May;40(2):193-206. doi: 10.1016/j.rdc.2014.01.003</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014 May;40(2):193-206. doi: 10.1016/j.rdc.2014.01.003</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi: 10.1002/art.27327</mixed-citation><mixed-citation xml:lang="en">Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-8. doi: 10.1002/art.27327</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164:464-71. doi: 10.7326/M14-2070</mixed-citation><mixed-citation xml:lang="en">Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164:464-71. doi: 10.7326/M14-2070</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis:</mixed-citation><mixed-citation xml:lang="en">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis:</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">a double-blind, randomized equivalence trial. Lancet. 2008;371:1854-60. doi: 10.1016/S0140-6736(08)60799-0</mixed-citation><mixed-citation xml:lang="en">a double-blind, randomized equivalence trial. Lancet. 2008;371:1854-60. doi: 10.1016/S0140-6736(08)60799-0</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49:670-7. doi: 10.1016/j.annemergmed.2006.11.014</mixed-citation><mixed-citation xml:lang="en">Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49:670-7. doi: 10.1016/j.annemergmed.2006.11.014</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang YK, Yang H, Zhang JY, et al. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014;68(5):633-8. doi: 10.1111/ijcp.12359</mixed-citation><mixed-citation xml:lang="en">Zhang YK, Yang H, Zhang JY, et al. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014;68(5):633-8. doi: 10.1111/ijcp.12359</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Федорова АА, Барскова ВГ, Якунина ИА, Насонова ВА. Кратковременное применение применение глюкокортикоидов</mixed-citation><mixed-citation xml:lang="en">Федорова АА, Барскова ВГ, Якунина ИА, Насонова ВА. Кратковременное применение применение глюкокортикоидов</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">у больных затяжным и хроническим подагрическим артритом. Часть III – частота развития нежелательных реакций. Научно-практическая ревматология. 2009;47(2):38-42 [Fedorova AA, Barskova VG, Yakunina IA, Nasonova VA. Short term administration of glucocorticoids in patients with protracted and chronic gout arthritis. Part III – frequency of adverse events. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(2):38-42 (In Russ.)]. doi: 10.14412/1995-4484-2009-457</mixed-citation><mixed-citation xml:lang="en">у больных затяжным и хроническим подагрическим артритом. Часть III – частота развития нежелательных реакций. Научно-практическая ревматология. 2009;47(2):38-42 [Fedorova AA, Barskova VG, Yakunina IA, Nasonova VA. Short term administration of glucocorticoids in patients with protracted and chronic gout arthritis. Part III – frequency of adverse events. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(2):38-42 (In Russ.)]. doi: 10.14412/1995-4484-2009-457</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010;11:2933-8. doi: 10.1517/14656566.2010.529432</mixed-citation><mixed-citation xml:lang="en">Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010;11:2933-8. doi: 10.1517/14656566.2010.529432</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Алекберова ЗС, Барскова ВГ. Колхицин в ревматолoгии – вчера и сегодня. Будет ли завтра? Современная ревматология. 2010;4(2):25-9 [Alekberova ZS, Barskova VG. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(2):25-9 (In Russ.)]. doi: 10.14412/1996-7012-2010-598</mixed-citation><mixed-citation xml:lang="en">Алекберова ЗС, Барскова ВГ. Колхицин в ревматолoгии – вчера и сегодня. Будет ли завтра? Современная ревматология. 2010;4(2):25-9 [Alekberova ZS, Barskova VG. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(2):25-9 (In Russ.)]. doi: 10.14412/1996-7012-2010-598</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Sivera F, Wechalekar MD, Andres M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009993. doi: 10.1002/14651858.CD009993.pub2</mixed-citation><mixed-citation xml:lang="en">Sivera F, Wechalekar MD, Andres M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009993. doi: 10.1002/14651858.CD009993.pub2</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Bardin T, So A, Alten R, et al. Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal AntiInflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT. Arthritis Rheum. 2012;64(10 Suppl):S811-2.</mixed-citation><mixed-citation xml:lang="en">Bardin T, So A, Alten R, et al. Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal AntiInflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT. Arthritis Rheum. 2012;64(10 Suppl):S811-2.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ, Барскова ВГ, Насонов ЕЛ. Опыт применения ингибитора интерлейкина1р канакинумаба</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Желябина ОВ, Барскова ВГ, Насонов ЕЛ. Опыт применения ингибитора интерлейкина1р канакинумаба</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">у больного с хронической тофусной подагрой. Научно-практическая ревматология. 2014;52(1):99-101 [Eliseev MS, Zhelyabin OV, Barskova VG, Nasonov EL. Experience of administration of canakinumab, an interleukin 1inhibitor, in a patient with chronic tophacaceous gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):99-101 (In Russ.)]. doi: 10.14412/1995-4484-2014-99-101</mixed-citation><mixed-citation xml:lang="en">у больного с хронической тофусной подагрой. Научно-практическая ревматология. 2014;52(1):99-101 [Eliseev MS, Zhelyabin OV, Barskova VG, Nasonov EL. Experience of administration of canakinumab, an interleukin 1inhibitor, in a patient with chronic tophacaceous gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):99-101 (In Russ.)]. doi: 10.14412/1995-4484-2014-99-101</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ, Мукагова МВ, Насонов ЕЛ. Клинический опыт применения блокатора интерлейкина 1кана-кинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22 [Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):16-22 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-16-22</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Желябина ОВ, Мукагова МВ, Насонов ЕЛ. Клинический опыт применения блокатора интерлейкина 1кана-кинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015;9(2):16-22 [Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):16-22 (In Russ.)]. doi: 10.14412/1996-7012-2015-2-16-22</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063</mixed-citation><mixed-citation xml:lang="en">Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 Jul;70(7):1264-71. doi: 10.1136/ard.2010.144063</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb random-ized, placebocontrolled trial. Circulation. 2012;126(23):2739-48. doi: 10.1161/CIRCULATIONAHA.112.122556</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb random-ized, placebocontrolled trial. Circulation. 2012;126(23):2739-48. doi: 10.1161/CIRCULATIONAHA.112.122556</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ, Маркелова ЕИ др. Оценка кардиоваскулярного риска при применении ингибитора интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология. 2016;10(1):7-14 [Eliseev MS, Zhelyabina OV, Markelova EI, et al. Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):7-14 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-7-14</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Желябина ОВ, Маркелова ЕИ др. Оценка кардиоваскулярного риска при применении ингибитора интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология. 2016;10(1):7-14 [Eliseev MS, Zhelyabina OV, Markelova EI, et al. Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):7-14 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-7-14</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеева МЕ, Цурко ВВ, Воробьев ПА. Пожилой пациент</mixed-citation><mixed-citation xml:lang="en">Елисеева МЕ, Цурко ВВ, Воробьев ПА. Пожилой пациент</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">с подагрой, лечение у терапевта. Клиническая геронтология. 2015;21(5-6):3-9 [Eliseeva ME, Tsurko VV, Vorob'ev PA. An elderly patient with gout, treatment with a therapist. Klinicheskaya Gerontologiya. 2015;21(5-6):3-9 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">с подагрой, лечение у терапевта. Клиническая геронтология. 2015;21(5-6):3-9 [Eliseeva ME, Tsurko VV, Vorob'ev PA. An elderly patient with gout, treatment with a therapist. Klinicheskaya Gerontologiya. 2015;21(5-6):3-9 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585-91. doi: 10.1080/15257770802136032</mixed-citation><mixed-citation xml:lang="en">Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585-91. doi: 10.1080/15257770802136032</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase IIItrials. Clin Ther. 2010;32:2386-97. doi: 10.1016/j.clinthera.2011.01.008</mixed-citation><mixed-citation xml:lang="en">Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase IIItrials. Clin Ther. 2010;32:2386-97. doi: 10.1016/j.clinthera.2011.01.008</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Crittenden DB, Kimmel JN, Pike VC, et al. Colchicine and risk of acute cardiovascular (CV) events among gout patients: the New York Department of veterans affairs retrospective cohort study. Arthritis Rheum. 2014;66(11 Suppl.):S65.</mixed-citation><mixed-citation xml:lang="en">Crittenden DB, Kimmel JN, Pike VC, et al. Colchicine and risk of acute cardiovascular (CV) events among gout patients: the New York Department of veterans affairs retrospective cohort study. Arthritis Rheum. 2014;66(11 Suppl.):S65.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon DH, Liu CC, Kuo IH, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-9.</mixed-citation><mixed-citation xml:lang="en">Solomon DH, Liu CC, Kuo IH, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-9.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1136/annrheumdis-2015-207984</mixed-citation><mixed-citation xml:lang="en">doi: 10.1136/annrheumdis-2015-207984</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679-85. doi: 10.1016/j.jacc.2013.01.055</mixed-citation><mixed-citation xml:lang="en">Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679-85. doi: 10.1016/j.jacc.2013.01.055</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low dose colchicine for secondary prevention of cardiovascular disease. JACC. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027</mixed-citation><mixed-citation xml:lang="en">Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low dose colchicine for secondary prevention of cardiovascular disease. JACC. 2013;61:404-10. doi: 10.1016/j.jacc.2012.10.027</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2017 May 9.</mixed-citation><mixed-citation xml:lang="en">Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2017 May 9.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1080/14397595.2017.1318467. [Epub ahead of print].</mixed-citation><mixed-citation xml:lang="en">doi: 10.1080/14397595.2017.1318467. [Epub ahead of print].</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy:results of a phase II random-ized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:876-84. doi: 10.1002/art.33412</mixed-citation><mixed-citation xml:lang="en">Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy:results of a phase II random-ized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:876-84. doi: 10.1002/art.33412</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, random-ized, placebo-controlled trial. Rheumatology (Oxford). 2013;52:1285-92. doi: 10.1093/rheumatology/ket114</mixed-citation><mixed-citation xml:lang="en">Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, random-ized, placebo-controlled trial. Rheumatology (Oxford). 2013;52:1285-92. doi: 10.1093/rheumatology/ket114</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 2012;64:1462-70. doi: 10.1002/acr.21690</mixed-citation><mixed-citation xml:lang="en">Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 2012;64:1462-70. doi: 10.1002/acr.21690</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.</mixed-citation><mixed-citation xml:lang="en">Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">J Rheumatol. 2014;41:1703-11. doi: 10.3899/jrheum.131226</mixed-citation><mixed-citation xml:lang="en">J Rheumatol. 2014;41:1703-11. doi: 10.3899/jrheum.131226</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Подагра. В кн.: Ревматология. Клинические российские рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 253-64 [Eliseev MS. Gout. In: Revmatologiya. Klinicheskie rossiiskie rekomendatsii [Rheumatology. Clinical Russian recommendations]. Moscow: GEOTAR-Media; 2017. P. 253-64].</mixed-citation><mixed-citation xml:lang="en">Елисеев МС. Подагра. В кн.: Ревматология. Клинические российские рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 253-64 [Eliseev MS. Gout. In: Revmatologiya. Klinicheskie rossiiskie rekomendatsii [Rheumatology. Clinical Russian recommendations]. Moscow: GEOTAR-Media; 2017. P. 253-64].</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91</mixed-citation><mixed-citation xml:lang="en">Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Насонова ВА, Елисеев МС, Барскова ВГ. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Современная ревматология. 2007;1(1):31-6 [Nasonova VA, Eliseev MS, Barskova VG. Impact of age on the frequency and magnitude of the signs of metabolic syndrome in patients with gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2007;1(1):31-6 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Насонова ВА, Елисеев МС, Барскова ВГ. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Современная ревматология. 2007;1(1):31-6 [Nasonova VA, Eliseev MS, Barskova VG. Impact of age on the frequency and magnitude of the signs of metabolic syndrome in patients with gout. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2007;1(1):31-6 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.14412/1996-7012-2007-436</mixed-citation><mixed-citation xml:lang="en">doi: 10.14412/1996-7012-2007-436</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Барскова ВГ, Елисеев МС, Зилов АВ, Насонов ЕЛ. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа. Ожирение и метаболизм. 2007;(1):19-23 [Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. The effect of hyperglycemia and hyperinsulinemia on the level of uric acid and the course of arthritis in patients with gout with type 2 diabetes mellitus.. Ozhirenie i Metabolizm. 2007;(1):19-23 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Барскова ВГ, Елисеев МС, Зилов АВ, Насонов ЕЛ. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа. Ожирение и метаболизм. 2007;(1):19-23 [Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. The effect of hyperglycemia and hyperinsulinemia on the level of uric acid and the course of arthritis in patients with gout with type 2 diabetes mellitus.. Ozhirenie i Metabolizm. 2007;(1):19-23 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Pillinger MH, Bangalore S, Klein AB, et al. Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. J Manag Care Spec Pharm. 2017;23(6):677-83. doi: 10.18553/jmcp.2017.23.6.677</mixed-citation><mixed-citation xml:lang="en">Pillinger MH, Bangalore S, Klein AB, et al. Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. J Manag Care Spec Pharm. 2017;23(6):677-83. doi: 10.18553/jmcp.2017.23.6.677</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2):156-60. doi: 10.1097/BOR.0b013e3283432d35</mixed-citation><mixed-citation xml:lang="en">Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2):156-60. doi: 10.1097/BOR.0b013e3283432d35</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, Schumacher H Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. doi: 10.1056/NEJMoa050373</mixed-citation><mixed-citation xml:lang="en">Becker MA, Schumacher H Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. doi: 10.1056/NEJMoa050373</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-8. doi: 10.1002/art.24209</mixed-citation><mixed-citation xml:lang="en">Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-8. doi: 10.1002/art.24209</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188-94. doi: 10.1093/rheumatology/ken457</mixed-citation><mixed-citation xml:lang="en">Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009;48:188-94. doi: 10.1093/rheumatology/ken457</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39:1450-7. doi: 10.3899/jrheum.111375</mixed-citation><mixed-citation xml:lang="en">Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39:1450-7. doi: 10.3899/jrheum.111375</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE. 2012;7:e50046.</mixed-citation><mixed-citation xml:lang="en">Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE. 2012;7:e50046.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1371/journal.pone.0050046</mixed-citation><mixed-citation xml:lang="en">doi: 10.1371/journal.pone.0050046</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93. doi: 10.2215/CJN.01580210</mixed-citation><mixed-citation xml:lang="en">Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93. doi: 10.2215/CJN.01580210</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014;25(2):316-20. doi: 10.4103/1319-2442.128520</mixed-citation><mixed-citation xml:lang="en">Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014;25(2):316-20. doi: 10.4103/1319-2442.128520</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30:217-26.</mixed-citation><mixed-citation xml:lang="en">Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30:217-26.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1111/j.1755-5922.2011.00277.x</mixed-citation><mixed-citation xml:lang="en">doi: 10.1111/j.1755-5922.2011.00277.x</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15:435 42. doi: 10.1111/j.1751-7176.2012.00701.x</mixed-citation><mixed-citation xml:lang="en">Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15:435 42. doi: 10.1111/j.1751-7176.2012.00701.x</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406-13.</mixed-citation><mixed-citation xml:lang="en">Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406-13.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1093/ndt/gft378</mixed-citation><mixed-citation xml:lang="en">doi: 10.1093/ndt/gft378</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. doi: 10.1186/s12882-015-0047-z</mixed-citation><mixed-citation xml:lang="en">Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. doi: 10.1186/s12882-015-0047-z</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015 Jul;74(7):1368-72. doi: 10.1136/annrheumdis-2014-205269</mixed-citation><mixed-citation xml:lang="en">Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015 Jul;74(7):1368-72. doi: 10.1136/annrheumdis-2014-205269</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161-7. doi: 10.1016/S0140-6736(10)60391-1</mixed-citation><mixed-citation xml:lang="en">Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161-7. doi: 10.1016/S0140-6736(10)60391-1</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a longterm follow-up study. Int J Clin Prac. 2009;63(9):1327-33.</mixed-citation><mixed-citation xml:lang="en">Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a longterm follow-up study. Int J Clin Prac. 2009;63(9):1327-33.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1111/j.1742-1241.2009.02118.x</mixed-citation><mixed-citation xml:lang="en">doi: 10.1111/j.1742-1241.2009.02118.x</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Gaffo AL, Dalbeth N, Saag KG, et al. Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study [abstract]. Arthritis Rheum. 2016;68 Suppl 10.</mixed-citation><mixed-citation xml:lang="en">Gaffo AL, Dalbeth N, Saag KG, et al. Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study [abstract]. Arthritis Rheum. 2016;68 Suppl 10.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82:141-3. doi: 10.1016/j.jbspin.2015.01.002</mixed-citation><mixed-citation xml:lang="en">Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82:141-3. doi: 10.1016/j.jbspin.2015.01.002</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57:1324-8. doi: 10.1002/art.23007</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57:1324-8. doi: 10.1002/art.23007</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-60. doi: 10.1002/art.10511</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-60. doi: 10.1002/art.10511</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Мукагова МВ, Смирнов АН и др. Атипичная подагра: тофусное поражение позвоночника. Научно-практическая ревматология. 2013;51(5):586-9 [Eliseev MS, Mukagova MV, Smirnov AV, et al. Atypical gout: spinal tophaceous injury. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):586-9 (In Russ.)]. doi: 10.14412/1995-4484-2013-1553</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Мукагова МВ, Смирнов АН и др. Атипичная подагра: тофусное поражение позвоночника. Научно-практическая ревматология. 2013;51(5):586-9 [Eliseev MS, Mukagova MV, Smirnov AV, et al. Atypical gout: spinal tophaceous injury. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):586-9 (In Russ.)]. doi: 10.14412/1995-4484-2013-1553</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Барскова ВГ, Елисеев МС. Больная хронической подагрой: комментарии к течению болезни. Современная ревматология. 2010;4(1):32-8 [Barskova VG, Eliseev MS. Patient with chronic gout: comments on the course of the disease. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(1):32-8 (In Russ.)]. doi: 10.14412/1996-7012-2010-584</mixed-citation><mixed-citation xml:lang="en">Барскова ВГ, Елисеев МС. Больная хронической подагрой: комментарии к течению болезни. Современная ревматология. 2010;4(1):32-8 [Barskova VG, Eliseev MS. Patient with chronic gout: comments on the course of the disease. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(1):32-8 (In Russ.)]. doi: 10.14412/1996-7012-2010-584</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007;46:1372-4. doi: 10.1093/rheumatology/kem056a</mixed-citation><mixed-citation xml:lang="en">Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007;46:1372-4. doi: 10.1093/rheumatology/kem056a</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Mironczuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2017;63(1):68-78. doi: 10.1016/j.advms.2017.05.005. [Epub ahead of print].</mixed-citation><mixed-citation xml:lang="en">Mironczuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2017;63(1):68-78. doi: 10.1016/j.advms.2017.05.005. [Epub ahead of print].</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13:453-60. doi: 10.1016/S1474-4422(14)70054-7</mixed-citation><mixed-citation xml:lang="en">Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13:453-60. doi: 10.1016/S1474-4422(14)70054-7</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69:1418-23. doi: 10.1212/01.wnl.0000277468.10236.f1</mixed-citation><mixed-citation xml:lang="en">Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69:1418-23. doi: 10.1212/01.wnl.0000277468.10236.f1</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:344-8. doi: 10.1002/gps.1469</mixed-citation><mixed-citation xml:lang="en">Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:344-8. doi: 10.1002/gps.1469</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Du N, Xu D, Hou X, et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer's Disease Risk. Mol Neurobiol. 2016;53(4):2594-9. doi: 10.1007/s12035-015-9271-6</mixed-citation><mixed-citation xml:lang="en">Du N, Xu D, Hou X, et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer's Disease Risk. Mol Neurobiol. 2016;53(4):2594-9. doi: 10.1007/s12035-015-9271-6</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169:1064-9. doi: 10.1093/aje/kwp033</mixed-citation><mixed-citation xml:lang="en">Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169:1064-9. doi: 10.1093/aje/kwp033</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166:561-7.</mixed-citation><mixed-citation xml:lang="en">Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166:561-7.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1093/aje/kwm127</mixed-citation><mixed-citation xml:lang="en">doi: 10.1093/aje/kwm127</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson's disease: A meta-analysis. PLoS One. 2017;12(3):e0173731. doi: 10.1371/journal.pone.0173731</mixed-citation><mixed-citation xml:lang="en">Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson's disease: A meta-analysis. PLoS One. 2017;12(3):e0173731. doi: 10.1371/journal.pone.0173731</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014;261:1133-8. doi: 10.1007/s00415-014-7331-x</mixed-citation><mixed-citation xml:lang="en">Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014;261:1133-8. doi: 10.1007/s00415-014-7331-x</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016 Mar;75(3):547-51.</mixed-citation><mixed-citation xml:lang="en">Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016 Mar;75(3):547-51.</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1136/annrheumdis-2014-206917. Epub 2015 Mar 4.</mixed-citation><mixed-citation xml:lang="en">doi: 10.1136/annrheumdis-2014-206917. Epub 2015 Mar 4.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One. 2014;9(4):e94084. doi: 10.1371/journal.pone.0094084. eCollection 2014.</mixed-citation><mixed-citation xml:lang="en">Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One. 2014;9(4):e94084. doi: 10.1371/journal.pone.0094084. eCollection 2014.</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Verhaaren BF, Vernooij MW, Dehghan A, et al. The relation of uric acid to brain atrophy and cognition: the Rotterdam Scan Study. Neuroepidemiology. 2013;41(1):29-34. doi: 10.1159/000346606</mixed-citation><mixed-citation xml:lang="en">Verhaaren BF, Vernooij MW, Dehghan A, et al. The relation of uric acid to brain atrophy and cognition: the Rotterdam Scan Study. Neuroepidemiology. 2013;41(1):29-34. doi: 10.1159/000346606</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11:R46. doi: 10.1186/ar2659</mixed-citation><mixed-citation xml:lang="en">Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11:R46. doi: 10.1186/ar2659</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609-13. doi: 10.1136/ard.2007.076182</mixed-citation><mixed-citation xml:lang="en">Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609-13. doi: 10.1136/ard.2007.076182</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the «dirty dish» hypothesis. Arthritis Rheum. 2011;63:4002-6. doi: 10.1002/art.30649</mixed-citation><mixed-citation xml:lang="en">Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the «dirty dish» hypothesis. Arthritis Rheum. 2011;63:4002-6. doi: 10.1002/art.30649</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis. 2013;72(5):638-45. doi: 10.1136/annrheumdis-2012-202301</mixed-citation><mixed-citation xml:lang="en">Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis. 2013;72(5):638-45. doi: 10.1136/annrheumdis-2012-202301</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Eliseev M, Zhelyabina O, Vladimirov S, et al. Ultrasonography signs of MSU urate deposition in patients with hyperuricemia and early diagnosis of gout. Ann Rheum Dis. 2016;75 Suppl 2:1183. doi: 10.1136/annrheumdis-2016-eular.4166</mixed-citation><mixed-citation xml:lang="en">Eliseev M, Zhelyabina O, Vladimirov S, et al. Ultrasonography signs of MSU urate deposition in patients with hyperuricemia and early diagnosis of gout. Ann Rheum Dis. 2016;75 Suppl 2:1183. doi: 10.1136/annrheumdis-2016-eular.4166</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Reinders MK, Haagsma C, Jansen T, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7. doi: 10.1136/ard.2008.091462</mixed-citation><mixed-citation xml:lang="en">Reinders MK, Haagsma C, Jansen T, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7. doi: 10.1136/ard.2008.091462</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51-6. doi: 10.1136/ard.2007.083071</mixed-citation><mixed-citation xml:lang="en">Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51-6. doi: 10.1136/ard.2007.083071</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi: 10.1186/ar2978</mixed-citation><mixed-citation xml:lang="en">Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. doi: 10.1186/ar2978</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Li S, Yang H, Guo Y, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Scientific Reports. 2016;6: Article number 33082. doi: 10.1038/srep33082</mixed-citation><mixed-citation xml:lang="en">Li S, Yang H, Guo Y, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Scientific Reports. 2016;6: Article number 33082. doi: 10.1038/srep33082</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-36. doi: 10.1002/art.34488</mixed-citation><mixed-citation xml:lang="en">Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-36. doi: 10.1002/art.34488</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Jutkowitz E, Alarid-Escudero F, Choi HK, et al. Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout. Ann Intern Med. 2014;16:617-26. doi: 10.7326/M14-0227</mixed-citation><mixed-citation xml:lang="en">Jutkowitz E, Alarid-Escudero F, Choi HK, et al. Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout. Ann Intern Med. 2014;16:617-26. doi: 10.7326/M14-0227</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Ryu H, Song R, Kim H, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2013;53:211-6. doi: 10.1177/0091270012439715</mixed-citation><mixed-citation xml:lang="en">Ryu H, Song R, Kim H, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2013;53:211-6. doi: 10.1177/0091270012439715</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheum. 2016;12:235-42. doi: 10.1038/nrrheum.2015.132</mixed-citation><mixed-citation xml:lang="en">Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheum. 2016;12:235-42. doi: 10.1038/nrrheum.2015.132</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Ramasamy SN, Korb-Wells CS, Kannangara DR, et al.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36:953-80. doi: 10.1007/s40264-013-0084-0</mixed-citation><mixed-citation xml:lang="en">Ramasamy SN, Korb-Wells CS, Kannangara DR, et al.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013;36:953-80. doi: 10.1007/s40264-013-0084-0</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74:2157-64.</mixed-citation><mixed-citation xml:lang="en">Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015;74:2157-64.</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1136/annrheumdis-2014-205577</mixed-citation><mixed-citation xml:lang="en">doi: 10.1136/annrheumdis-2014-205577</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-40. doi: 10.1007/s11926-009-0019-z</mixed-citation><mixed-citation xml:lang="en">Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-40. doi: 10.1007/s11926-009-0019-z</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-8. doi: 10.1136/annrheumdis-2016-210872</mixed-citation><mixed-citation xml:lang="en">Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-8. doi: 10.1136/annrheumdis-2016-210872</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-21. doi: 10.1002/art.30119</mixed-citation><mixed-citation xml:lang="en">Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-21. doi: 10.1002/art.30119</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-50.</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-50.</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96:90-8. doi: 10.1159/000434633</mixed-citation><mixed-citation xml:lang="en">Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96:90-8. doi: 10.1159/000434633</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58:2882-91. doi: 10.1002/art.23810</mixed-citation><mixed-citation xml:lang="en">Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58:2882-91. doi: 10.1002/art.23810</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60. doi: 10.1186/ar4497</mixed-citation><mixed-citation xml:lang="en">Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60. doi: 10.1186/ar4497</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Барскова ВГ, Якунина ИА. Диагноз подагра –противопоказние к назначению диуретиков. Фарматека. 2003;(5):67-70 [Eliseev MS, Barskova VG, Yakunina IA. Diagnosis of gout – contraindications to the appointment of diuretics. Farmateka. 2003;(5):67-70 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Елисеев МС, Барскова ВГ, Якунина ИА. Диагноз подагра –противопоказние к назначению диуретиков. Фарматека. 2003;(5):67-70 [Eliseev MS, Barskova VG, Yakunina IA. Diagnosis of gout – contraindications to the appointment of diuretics. Farmateka. 2003;(5):67-70 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Ranieri L, Contero C, Andres M. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Ann Rheum Dis. 2017;6 Suppl 2:372. doi: 10.1136/annrheumdis-2017-eular.3905</mixed-citation><mixed-citation xml:lang="en">Ranieri L, Contero C, Andres M. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Ann Rheum Dis. 2017;6 Suppl 2:372. doi: 10.1136/annrheumdis-2017-eular.3905</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. doi: 10.1136/bmj.d8190</mixed-citation><mixed-citation xml:lang="en">Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. doi: 10.1136/bmj.d8190</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63-70. doi: 10.1016/j.phrs.2015.09.012</mixed-citation><mixed-citation xml:lang="en">Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63-70. doi: 10.1016/j.phrs.2015.09.012</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904-13.</mixed-citation><mixed-citation xml:lang="en">Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904-13.</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1053/j.ajkd.2008.01.014</mixed-citation><mixed-citation xml:lang="en">doi: 10.1053/j.ajkd.2008.01.014</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">Ogata N, Fujimori S, Oka Y, et al. Effects of three strong statins(atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29:321-4. doi: 10.1080/15257771003741323</mixed-citation><mixed-citation xml:lang="en">Ogata N, Fujimori S, Oka Y, et al. Effects of three strong statins(atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29:321-4. doi: 10.1080/15257771003741323</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157:255-7. doi: 10.1016/j.ijcard.2012.01.092</mixed-citation><mixed-citation xml:lang="en">Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157:255-7. doi: 10.1016/j.ijcard.2012.01.092</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
